Claims for Patent: 8,571,805

Summary for Patent: 8,571,805

Title:	Method and apparatus for detecting and regulating vascular endothelial growth factor (VEGF) by forming a homeostatic loop employing a half-antibody biosensor
Abstract:	A biosensor for detection of vascular endothelial growth factor (VEGF) hybridization uses an array of parallel capacitors to detect electrochemical binding of circulating VEGF to immobilized anti-VEGF monoclonal half-antibodies (a-VEGF mhAb). Binding of a-VEGF mhAb modulates the threshold voltage of a circuit, changing the impedance of the circuit. An electrode coated with a p-Si substrate enhances the affinity between the VEGF molecules. A fluid cell delivers VEGF samples onto the active surface of the chip. An array of parallel capacitors arranged in an interdigitated pattern detects the VEGF in the fluid. The detector provides an accurately measured and quantifiable rate of change of the VEGF molecules in vivo, providing real time feedback which is used to measure response of the tumor to delivered chemotherapeutic agents and biological response modifiers (BRMs) for the purpose of determining tumor burden and efficacy of the chemotherapy as part of a homeostatic loop for chemotherapy.
Inventor(s):	Shachar; Yehoshua (Santa Monica, CA), Wu; Winston (Alhambra, CA), Chen; Thomas (La Canada, CA), Jordan; Brett (Los Angeles, CA), Zimmerman; Kyle (Los Angeles, CA), Chan; Herwin (Los Angeles, CA), Luboff; Paladin (Santa Monica, CA)
Assignee:	Pharmaco-Kinesis Corporation (Century City, CA)
Application Number:	12/820,830
Patent Claims:	1. An anti-VEGF monoclonal half-antibody (a-VEGF mhAb) probe complex for detecting the presence of a target VEGF molecule in a detector, the probe complex comprising: an electrode in the detector; and a-VEGF mhAb on the electrode capable of binding to indicator VEGF protein and capable of immobilizing the indicator VEGF protein to enable detection of the target VEGF molecule by the detector. 2. The a-VEGF mhAb probe complex of claim 1 where the a-VEGF mhAb enables binding with high specificity to VEGF protein, and further comprising a circuit coupled to the electrode to selectively release the binding to the VEGF protein by application of electric current to the electrode and to thereby allow for re-use of the probe complex. 3. The a-VEGF mhAb probe complex of claim 1 where the a-VEGF mhAb enables binding with high specificity to VEGF protein, and further comprising a fluidic circuit to selectively release the binding by application of fluid flow provided by the fluidic circuit. 4. The a-VEGF mhAb probe complex of claim 2 where the a-VEGF mhAb enables binding with high specificity to VEGF protein, and further comprising a fluidic circuit to selectively release the binding by application of fluid flow provided by the fluidic circuit. 5. The a-VEGF mhAb probe complex of claim 4 in combination with a source of fluid and where the fluidic circuit to selectively release the binding by application of fluid flow provided by the fluidic circuit comprises a piezoelectric pump having an input fluidicly coupled to the source of fluid and an output fluidicly coupled to the electrode, the piezoelectric pump and, electrode being arranged and configured to allow fluidic flushing of the electrode by fluid flow provided by the piezoelectric pump. 6. The a-VEGF mhAb probe complex of claim 1 where the a-VEGF mhAb is composed of chemically split Avastin.RTM.. 7. The a-VEGF mhAb probe complex of claim 1 where the a-VEGF mhAb is composed of chemically split humanized monoclonal antibody VEGF (rhuMab VEGF; bevacizumab). 8. The a-VEGF mhAb probe complex of claim 1 where the detector includes a silicon substrate and further comprising a linker composed of a-VEGF mhAB attached to maleimide-terminated self assembled monolayer (m-SAM) bonded to the silicon substrate by silanization with an amine group. 9. A sensor array of a target comprising: a substrate; a plurality of insulated micro machined capacitors on at least a portion of which the substrate is disposed, the capacitors being arranged in an interdigitated pattern; a recognition group attached to the plurality of capacitors, the recognition group specifically binding to the target; a detector circuit for sensing the plurality of capacitors; and means for reconfiguring the recognition group to allow for reuse of the sensor array. 10. The sensor array of claim 9 where at least one of the plurality of capacitors has a plurality of areas, each of the plurality of areas having a recognition group attached to the area and further comprising a circuit coupled to the plurality of areas to selectively release the binding to the target by application of electric current to the plurality of capacitors and to thereby allow for reuse of the sensor array. 11. The sensor array of claim 9 further comprising a fluidic circuit to selectively release the binding of the recognition group by application of fluid flow provided by the fluidic circuit. 12. The sensor array of claim 11 further comprising a fluidic circuit to selectively release the binding of the recognition group by application of fluid flow provided by the fluidic circuit. 13. The sensor array of claim 12 in combination with a source of fluid and where the fluidic circuit utilized to selectively release the binding of the recognition group by application of fluid flow provided by the fluidic circuit comprises a piezoelectric pump having an input fluidicly coupled to the source of fluid and an output fluidicly coupled to the plurality of capacitors, the piezoelectric pump and the plurality of capacitors being arranged and configured to allow fluidic flushing of the electrode by fluid flow provided by the piezoelectric pump. 14. The sensor array of claim 9 where the recognition group is composed of chemically split Avastin.RTM.. 15. The sensor array of claim 9 where the recognition group is composed of chemically split humanized monoclonal antibody VEGF (rhuMab VEGF; bevacizumab). 16. The sensor array of claim 9 where the recognition group comprises a-VEGF mhAb capable of binding to indicator VEGF protein and capable of immobilizing the indicator VEGF protein on the capacitors to enable detection of the target VEGF molecule by the detector. 17. The sensor array of claim 9 further comprising a microcontroller coupled to the sensor array and where at least one of the plurality of capacitors has a recognition group that binds to the target and the detector detects presence of the target on at least one of the capacitors and communicates detection of the target to the microcontroller. 18. The sensor array of claim 16 further comprises a linker disposed on at least a portion of at least one capacitor to immobilize a-VEGF mhAb on the at least one capacitor. 19. The sensor array of claim 18 where the linker comprises Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate, and a hybridization substance (3-aminopropyl-trimethoxysilane). 20. A system for detecting a target of a-VEGF mhAb in a fluid comprising: a sensor comprising: a substrate; a sealed micromachined mesh capacitor array on at least a portion of which the substrate is disposed; a recognition group attached to the substrate, the recognition group selectively binding to the target of a-VEGF mhAb; and a detector for detecting binding of the target of a-VEGF mhAb by the recognition group; a delivery system for delivering the fluid for analysis to the sensor; and means for reconfiguring the recognition group to allow for selective release of the target to allow reuse of the sensor array. 21. The system of claim 20 where the delivery system includes an input port, a reservoir for the fluid connected to the input port, and an output port connected to the reservoir, at least a portion of the substrate being exposed to the fluid in the reservoir. 22. The system of claim 20 where the capacitor array has a predetermined capacitance selected to enable target binding of a maximum amount of functionalized surface area of the capacitor array, and where the delivery system is dimensionally and structurally arranged and configured as a function of the predetermined capacitance to provide unrestricted flow of the fluid through the sensor. 23. The system of claim 20 where the means for reconfiguring the recognition group to allow for selective release of the target to allow reuse of the sensor array comprises a circuit coupled to the plurality of areas to selectively release the binding to the target by application of electric current to the capacitor array and to thereby allow for reuse of the sensor array, or a fluidic circuit to selectively release the binding by application of fluid flow provided by the fluidic circuit. 24. A method of real-time in vivo detection of VEGF in patient fluid comprising: chemically splitting humanized monoclonal antibody VEGF (rhuMab VEGF; bevacizumab); attaching the split humanized monoclonal antibody VEGF to capacitor surfaces in a sensor; exposing the sensor to a fluid including VEGF to be analyzed using the split humanized monoclonal antibody VEGF; binding the VEGF to the measurement surfaces within the sensor by binding the VEGF to the split humanized monoclonal antibody VEGF to form a ligand hybridized target VEGF as an analyte molecule; and detecting the analyte molecule to measure the hybridized target VEGF; and generating an output from the sensor indicative of the measured hybridized target VEGF. 25. The method of claim 24 where chemically splitting humanized monoclonal antibody VEGF (rhuMab VEGF; bevacizumab) comprises chemically splitting Avastin.RTM.. 26. The method of claim 24 where detecting the analyte molecule comprises detecting a change in a capacitive value of the sensor through changes in a magnitude of sensor impedance, or time rate of change of sensor impedance. 27. The method of claim 24 where chemically splitting humanized monoclonal antibody VEGF (rhuMab VEGF; bevacizumab) comprises splitting an anti-VEGF monoclonal antibody (a-VEGF mAb) into two half-antibodies by using tris (2-carboxyethyl) phosphine (TCEP) as reduction agent to selectively cleave disulfide bonds that connect the two heavy chains of a mAB to produce two anti-VEGF half-antibodies (mhAb). 28. The method of claim 24 further comprising providing guided therapeutic intervention of at least one medicating agent dependent on the real-time in vivo detection of VEGF in patient fluid.

Details for Patent 8,571,805

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2039-03-29